---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-028025"
form_type: "8-K"
ticker: null
cik: "0000879682"
company_name: "VIVEVE MEDICAL, INC."
filed_at: "2022-11-23T23:59:59+00:00"
generated_at: "2026-06-21T13:43:58.971004+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Viveve Medical receives Nasdaq deficiency notice for stockholders' equity below $2.5M

## Summary
- Reported stockholders' equity of $1,184,000 as of Sept 30, 2022, below Nasdaq's $2,500,000 minimum.
- Nasdaq gave company 45 days (until Jan 3, 2023) to submit a plan to regain compliance.
- If plan accepted, company has up to 180 days from Nov 18, 2022 to evidence compliance.
- Company also previously disclosed non-compliance with minimum bid price rule ($1.00/share) on June 3, 2022.
- No assurance of regaining compliance; failure could lead to delisting and hearing rights.

## SEC filing metadata
- accession: 0001437749-22-028025
- form_type: 8-K
- cik: 0000879682
- company_name: VIVEVE MEDICAL, INC.
- filed_at: 2022-11-23T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879682/000143774922028025/0001437749-22-028025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879682/000143774922028025/vive20221122_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-028025
- JSON: https://secwatch.observer/filing/0001437749-22-028025.json
- Plain text: https://secwatch.observer/filing/0001437749-22-028025.txt

## Key facts
- Listing & Compliance Notices
  VIVEVE MEDICAL, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: November 18, 2022, Viveve Medical, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. In its quarterly report on Form 10-Q for the quarter ended September 30, 2022 filed with the Securities and Exchange Commission (the “Commission”) on November 10, 2022, the Company reported stockholders’ equity of $1,184,000, and, as a result, does not currentl
  evidence_url: https://www.sec.gov/Archives/edgar/data/879682/000143774922028025/0001437749-22-028025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.